A Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer. (NCT06629779)

🧪 Interventions in This Study

• PF-06821497 (DRUG)
• Placebo (DRUG)
• Enzalutamide (DRUG)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (236 Sites)

Showing the first 25 of 236 sites.

• Ironwood Cancer & Research Centers — Chandler, Arizona
• Ironwood Cancer & Research Centers — Gilbert, Arizona
• Palo Verde Hematology Oncology — Glendale, Arizona
• Ironwood Cancer & Research Centers — Glendale, Arizona
• Ironwood Cancer & Research Centers — Goodyear, Arizona
• Ironwood Cancer & Research Centers — Mesa, Arizona
• Ironwood Cancer & Research Centers — Mesa, Arizona
• Ironwood Cancer & Research Centers — Phoenix, Arizona
• Ironwood Cancer & Research Centers — Scottsdale, Arizona
• Highlands Oncology — Fayetteville, Arkansas
• Arkansas Urology - Little Rock — Little Rock, Arkansas
• Highlands Oncology — Rogers, Arkansas
• Highlands Oncology Group — Springdale, Arkansas
• Los Angeles Cancer Network (LACN) — Anaheim, California
• Los Angeles Cancer Network (LACN) — Fountain Valley, California
• Los Angeles Cancer Network (LACN) — Glendale, California
• Los Angeles Cancer Network (LACN) — Glendale, California
• Los Angeles Cancer Network (LACN) — Laguna Hills, California
• Los Angeles Cancer Network (LACN) — Los Angeles, California
• Los Angeles Cancer Network (LACN) — Los Angeles, California
• Medical Oncology Associates of San Diego — San Diego, California
• Accellacare of Duly — Lisle, Illinois
• Duly Health and Care (Bone Scintigraphy) — Lisle, Illinois
• Blessing Hospital — Quincy, Illinois
• Blessing Physician Services — Quincy, Illinois

📞 Contact the Study Coordinator

Phone: (800) 718-1021

Email: ClinicalTrials.gov_Inquiries@pfizer.com

Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Metastatic Castration-Resistant Prostate Cancer

• A Study of Copanlisib Combined With Rucaparib in Patients With Metastatic Castration-resistant Prostate Cancer — San Francisco, California
• Study Evaluating mCRPC Treatment Using PSMA [Lu-177]-PNT2002 Therapy After Second-line Hormonal Treatment — Tucson, Arizona
• ONC-392 Plus Lutetium Lu 177 Vipivotide Tetraxetan in Patients With mCRPC — Sacramento, California
• FPI-2265 (225Ac-PSMA-I&T) for Patients With PSMA-Positive Metastatic Castration-Resistant Prostate Cancer (mCRPC) — Duarte, California
• A Study to Assess Adverse Events, and How Intravenously (IV) Infused ABBV-969 Moves Through the Bodies of Adult Participants With Metastatic Castration-Resistant Prostate Cancer — Duarte, California
• FOR46 in Combination With Enzalutamide in Patients With Metastatic Castration Resistant Prostate Cancer — San Francisco, California

Explore by condition: All Metastatic Castration-Resistant Prostate Cancer clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Contact the study coordinator using the phone/email above.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.